Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE:000623)

SHE:000623 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,307	2,537	3,404	2,850	2,263	2,237
Other Revenue	18.68	73.86	45.58	17.95	41.05	15.11
Revenue	2,325	2,611	3,449	2,868	2,304	2,252
Revenue Growth (YoY)	-29.06%	-24.31%	20.25%	24.50%	2.31%	-27.09%
Cost of Revenue	1,315	1,602	1,768	1,417	1,111	929.01
Gross Profit	1,010	1,008	1,681	1,451	1,193	1,323
Selling, General & Admin	1,078	1,055	1,354	1,181	1,093	1,279
Research & Development	74.18	82.2	124.98	85.68	49.42	67.21
Other Operating Expenses	71.63	37.28	46.43	42.77	39.3	43.02
Operating Expenses	1,220	1,169	1,546	1,321	1,187	1,388
Operating Income	-209.78	-160.4	134.53	129.91	5.87	-65.74
Interest Expense	-53.49	-92.08	-144.35	-142.99	-130.49	-126.82
Interest & Investment Income	2,219	1,877	1,382	1,697	2,070	1,916
Other Non Operating Income (Expenses)	-1.83	7.42	107.65	589.79	-7.62	-5.28
EBT Excluding Unusual Items	1,954	1,632	1,479	2,274	1,937	1,718
Impairment of Goodwill	-	-	-	-	-	-24.28
Gain (Loss) on Sale of Investments	393.29	-121.67	-111.06	-632.66	-259.53	-75.98
Gain (Loss) on Sale of Assets	-0.28	-0.67	36.16	3.16	-0.94	-0.64
Asset Writedown	-65.54	-65.33	-3.25	-1.25	-2.84	-1.25
Other Unusual Items	106.41	77.54	98.83	77.92	92.6	100.79
Pretax Income	2,388	1,521	1,500	1,721	1,767	1,717
Income Tax Expense	108.12	2.23	55.83	-80.16	-4.19	25.14
Earnings From Continuing Operations	2,280	1,519	1,444	1,801	1,771	1,691
Minority Interest in Earnings	15.89	32.2	15.54	-20.2	9.64	17.46
Net Income	2,295	1,551	1,460	1,781	1,781	1,709
Net Income to Common	2,295	1,551	1,460	1,781	1,781	1,709
Net Income Growth	145.73%	6.27%	-18.02%	0.02%	4.19%	21.75%
Shares Outstanding (Basic)	1,184	1,177	1,125	1,135	1,139	1,158
Shares Outstanding (Diluted)	1,184	1,177	1,295	1,301	1,259	1,276
Shares Change (YoY)	-3.48%	-9.08%	-0.46%	3.36%	-1.39%	-0.28%
EPS (Basic)	1.94	1.32	1.30	1.57	1.56	1.48
EPS (Diluted)	1.94	1.32	1.23	1.47	1.51	1.43
EPS Growth	138.30%	7.39%	-16.35%	-2.93%	5.70%	20.92%
Free Cash Flow	80.36	-214.5	-351.46	152.89	11.54	163.02
Free Cash Flow Per Share	0.07	-0.18	-0.27	0.12	0.01	0.13
Dividend Per Share	0.500	0.500	0.600	0.300	0.300	0.200
Dividend Growth	-37.50%	-16.67%	100.00%	-	50.00%	-
Gross Margin	43.43%	38.62%	48.74%	50.59%	51.76%	58.74%
Operating Margin	-9.02%	-6.14%	3.90%	4.53%	0.26%	-2.92%
Profit Margin	98.72%	59.43%	42.33%	62.09%	77.29%	75.89%
Free Cash Flow Margin	3.46%	-8.22%	-10.19%	5.33%	0.50%	7.24%
EBITDA	-13	45.48	339.83	326.49	200.39	129.73
EBITDA Margin	-0.56%	1.74%	9.85%	11.38%	8.70%	5.76%
D&A For EBITDA	196.78	205.88	205.3	196.58	194.53	195.46
EBIT	-209.78	-160.4	134.53	129.91	5.87	-65.74
EBIT Margin	-9.02%	-6.14%	3.90%	4.53%	0.26%	-2.92%
Effective Tax Rate	4.53%	0.15%	3.72%	-	-	1.47%
Revenue as Reported	2,325	2,611	3,449	2,868	2,304	2,252
Advertising Expenses	-	183.98	277.99	202.59	160.73	212.53

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.